2017
Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease
Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney International Reports 2017, 2: 1050-1058. PMID: 29270514, PMCID: PMC5733827, DOI: 10.1016/j.ekir.2017.06.002.Peer-Reviewed Original ResearchEnd-stage renal diseasePlasma oxalate concentrationRenal diseaseCalcium oxalate supersaturationPlasma of patientsTraditional therapeutic regimensExtended treatment timeTherapeutic regimensExtended hemodialysisUremic toxin removalHemodialysisTherapeutic strategiesTreatment sessionsPatientsBaseline pDialysis equipmentHemodialfiltrationWeeksTreatment timeOxalate concentrationRespective treatmentsDiseasePrevious reportsTreatment modeHours
2006
Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6
Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nature Genetics 2006, 38: 474-478. PMID: 16532010, DOI: 10.1038/ng1762.Peer-Reviewed Original ResearchConceptsCalcium oxalate urolithiasisOxalate urolithiasisPlasma oxalate concentrationIntestinal oxalate secretionUrinary oxalate concentrationCommon urologic diseaseNet intestinal absorptionAnion exchanger SLC26A6Dietary oxalate restrictionSlc26a6-null miceSignificant hyperoxaluriaOxalate restrictionUrologic diseasesHigh incidenceIntestinal absorptionExchanger SLC26A6Mutant miceUrolithiasisMiceMajor constitutive roleNet absorptionOxalate secretionHyperoxaluriaOxalate concentrationEpithelial tissues